Medpace Holdings (NASDAQ:MEDP) exceeded market expectations with Q2 CY2025 revenue up 14.2% to $603.3 million. Full-year revenue guidance of $2.47 billion is 13% above analyst estimates. GAAP profit of $3.10 per share beat estimates by 3.5%. Operating margin increased to 20.9%, EPS grew at 36.7% CAGR over five years. While revenue growth is strong at 14.2%, EPS is expected to decline by 8.1% over the next 12 months. Medpace’s stock price surged 46% to $451 post-earnings. Analysts are cautious about future revenue decline. Access our full research report for more insights.

Read more at StockStory Org: Medpace (NASDAQ:MEDP) Reports Strong Q2, Stock Jumps 46%